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Abstract
The increased susceptibility of the elderly to infection presents a major challenge to public health
services. An aging immune system is well documented as the cause of increased infection rates in
elderly people. Such immunosenescence is multi-factorial and incompletely understood.
Immunosenescent changes include malfunctioning of innate immune system cellular receptors;
involution of the thymus, with consequent reduction of the naïve T cell population; alteration of
the T cell population composition; modified phenotypes of individual T cells; and replicative
senescence of memory cells expressing naïve markers. Unfortunately, immunosenescence also
renders vaccination less effective in the elderly. It is therefore important that the vaccines used
against common but preventable diseases, such as influenza, are specifically enhanced to overcome
the reduced immune responsiveness of this vulnerable population.
1. Introduction
The global population is aging and the percentage of the
population that is elderly (≥60 years of age) now forms a
larger proportion than ever before. Analysis undertaken
by the United Nations has shown that the percentage of
elderly people worldwide has increased from 8% in 1950
to 10% in 2000; this trend is expected to continue, with
21% of the population being elderly by 2050 [1].
The aging population presents a challenge for the public
healthcare system, as the elderly suffer from more fre-
quent and severe infections than younger people [2]. Fur-
thermore, elderly people tend to experience poor
outcomes from infections in comparison to the younger
population. In particular, influenza is an example of a
common infection which causes annual epidemics, and in
the elderly, is associated with increased morbidity.
Indeed, influenza is one of the ten major causes of death
in the elderly [2].
One of the main reasons for the increase in infections
observed in the elderly is believed to be immunosenes-
cence [2]. This term was introduced by Dr. Roy Walford
[3] and refers to the immune system's diminished func-
tion with age [4], which leads to a decline in the response
to infection by both the innate and adaptive immune sys-
tems. This phenomenon, however, is not yet fully under-
stood [5].
As the immune response in the elderly declines and the
outcome of infection is often poor, prevention of infec-
tions becomes critically important [4]. Vaccination can
Published: 11 December 2007
Immunity & Ageing 2007, 4:9 doi:10.1186/1742-4933-4-9
Received: 6 September 2007
Accepted: 11 December 2007
This article is available from: http://www.immunityageing.com/content/4/1/9
© 2007 Aspinall et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Immunity & Ageing 2007, 4:9 http://www.immunityageing.com/content/4/1/9
Page 2 of 9
(page number not for citation purposes)
protect the elderly against diseases such as influenza, and
in this case is recommended by the World Health Organ-
ization [6] and other health authorities. However, immu-
nosenescence also affects the response to immunisation,
as shown by the reduced efficacy of annual influenza vac-
cination in the elderly, with an efficacy of 17–53% in the
elderly, compared with 70–90% in healthy adults [7].
The effects of immunosenescence on the innate immune
response, the generation of T cells, the adaptive immune
response, and the response to vaccination are discussed
here, highlighting the need for a better understanding of
the effects of aging on the immune response and the
development of more effective vaccines that target the eld-
erly.
2. Aging changes innate immunity
Innate immunity is a key element of the immune
response; it prevents the entry of pathogens into the
body's tissues, rapidly removes microorganisms if they
gain access into the tissues, and instructs the adaptive
immune system to mount pathogen-specific humoral and
cellular immune responses. The innate immune system
includes several cellular components such as macro-
phages, natural killer cells, and neutrophils, which pro-
vide first-line defence against bacterial and viral infections
[8]. The function of these cells declines with age, which
may offer an explanation for the increased incidence of
gastrointestinal and skin infections, as well as an increase
in bacterial and viral pneumonias observed in the elderly.
Immunosenescence of the innate immune system may
also contribute to the reduced response to vaccination,
such as for influenza; while influenza vaccination has 70–
90% efficacy in healthy adults, this falls to 17–53% in the
elderly [7]. This reduced efficacy is due to changes in the
microenvironment leading to suboptimal stimulation of
the adaptive immune system.
The innate immune system detects pathogens using pat-
tern-recognition receptors, such as toll-like receptors
(TLR), which recognise specific molecular patterns
present on the surface of pathogens triggering a variety of
signalling pathways. TLR are evolutionarily conserved
molecules expressed on a variety of cells, such as macro-
phages, and form a large family of related molecules [8,9].
Interaction between a TLR and a pathogen stimulates the
secretion of a wide range of antibacterial peptides that
destroy the pathogen and trigger an inflammatory
response [9]. Changes in the expression and function of
TLR as a result of immunosenescence, leading to dysregu-
lated pro-inflammatory cytokine and chemokine secre-
tion, may explain why the elderly fail to exhibit classical
symptoms of some infectious diseases. Furthermore, alter-
ation in the functioning of TLR may interrupt instruction
of the adaptive immune system, resulting in an inade-
quate response.
Studies comparing macrophage TLR from young and old
mice using an in vitro system have shown that expression
and function of these receptors declines with age [8]. Fur-
thermore, there is a decrease in the secretion of pro-
inflammatory cytokines in aged mice, which is replicated
in frail, elderly people (Figure 1) [10]. These findings
demonstrate the impact of immunosenescence on the
expression and function of TLR, resulting in changes
which affect the innate immune response, which in turn
affect the adaptive response. Therefore, modulation of the
innate immune system either with TLR ligands or the
products of TLR activation may enhance disease resist-
ance, immune response and vaccine effectiveness in the
elderly.
3. Immunosenescence affects the response to 
vaccines
In a young healthy adult (<30 years of age) there are
approximately 3 × 1011 T cells, of which 1–2% can be
found within the blood, and up to 50% are within the
antigen-naïve population. During a successful response,
activation of these antigen-naïve T cells leads to their
clonal expansion, the generation of effector cells and the
subsequent reduction in the amount and source of the
antigen. This is followed by a period of cell death since the
immune system no longer requires large numbers of T
cells bearing that specific antigen receptor; however, some
cells remain and become memory T cells that subse-
quently enter the memory T cell pool. Repeated exposure
of the immune system to a potential pathogen will be met
by these memory T cells and will lead to a response that is
more rapid and of greater magnitude than the response
following the initial exposure. As there are few completely
sterile environments, each of us is confronted on a daily
basis with different organisms. Thus, our survival depends
upon our immune system recognising and responding
successfully to a broad range of potential pathogens. Pro-
vided these pathogens do not result in our death, our
immunological memory should increase; indeed, analysis
shows that aging is associated with an increase in the
number of memory T cells. Theoretically then, with this
increased memory T cell pool, we should be able to cope
with more infections as we get older. Unfortunately this
does not seem to be the case. Evidence from epidemiolog-
ical, clinical and laboratory studies suggest an age-related
defect in the immune system. The epidemiological evi-
dence reveals that older individuals are often the first to be
affected by new or emerging pathogens such as West Nile
virus [11]. During an epidemic of West Nile virus in the
United States in 2002, the majority of cases occurred in
those over 50 years of age. The epidemic caused 4156
cases, of which 284 were fatal; the median age of theImmunity & Ageing 2007, 4:9 http://www.immunityageing.com/content/4/1/9
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deceased was 78 years of age [12]. Clinicians recognise
that in addition to this susceptibility to new pathogens,
older individuals often have difficulties in dealing with
pathogens which they have previously overcome, includ-
ing the annual return of influenza. Although influenza
infection is considered to be a self-limiting contagious
viral-mediated disease of the respiratory tract, it is associ-
ated with considerable morbidity and mortality in the eld-
erly. Those >65 years of age account for >90% of the
deaths from influenza and are more likely to develop
complications such as pneumonia following infection
[13].
Such age-associated dysfunctions are preceded by a meas-
urable decline in thymic export of αβ+ T cells [14,15] to
the naïve T cell pool, which declines with age due to the
combination of the limited lifespan of naïve cells, reduced
thymic function, and recruitment of naïve cells into acti-
vated and memory T cell pools. Homeostatic mecha-
nisms, however, ensure that numbers within the total T
Monocytes from frail elderly subjects secrete reduced levels of proinflammatory cytokines and chemokines in response to toll- like receptors (TLR) ligation Figure 1
Monocytes from frail elderly subjects secrete reduced levels of proinflammatory cytokines and chemokines in 
response to toll-like receptors (TLR) ligation. TNF-α, tumour necrosis factor alpha; IL-6, interleukin-6; IL-8, interleukin-
8; MCP-1, monocyte chemotactic protein-1; LPS, lipopolysaccharide; Zym, zymosan; Poly I:C, polyinosinic-polycytidylic acid; 
R848, resiquimod; Med, medium alone. Results are from 1 × 106 monocytes from nine young and nine elderly individuals stim-
ulated with various TLR ligands and analyses of culture supernatants 48 hours post-stimulation. The error bars represent 
standard error of means.Immunity & Ageing 2007, 4:9 http://www.immunityageing.com/content/4/1/9
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cell pool are maintained through life within specific lim-
its, so a decrease in naïve T cell numbers is matched by an
increase in the number of memory T cells [16,17] and
senescent T cells [18].
The age-associated alteration in the number of naïve T
cells emerging from the thymus is thought to be caused by
changes in the thymic microenvironment that prevent
thymopoiesis. One element recently implicated in these
changes is interleukin-7 (IL-7) [19]. IL-7 has a central role
in the production of T cells. The receptor for IL-7, which
comprises a common γ chain and an α chain, is expressed
during the intrathymic T cell developmental pathway
[20]. Interaction between IL-7 and its receptor at early
stages of the T cell pathway has been reported to aid cell
survival [21] and also act as a cofactor in recombination
events [22]. At later thymocyte stages, this interaction may
act to expand positively selected thymocytes [23]. An age-
related reduction in production of IL-7 within the thymus
[19,24] contributes to the reduced survival of thymocytes
[25] and it is this reduction which produces the age-
related decline both in thymic size and thymic output.
The decline in IL-7 expression levels makes it a target for
therapeutic interventions to rejuvenate thymopoiesis in
the elderly. Previous work has shown that IL-7 can reverse
the atrophy of the thymus in old animals, ensuring
increased thymic output to the peripheral T cell pool and
improving immune responses [25]. The normal therapeu-
tic approach has been to inject IL-7 subcutaneously so that
it will diffuse through the organs and tissues of the body
to reach its target organ. This approach is inefficient
because of the low concentration of IL-7 that eventually
reaches the thymus. As with most therapeutic agents, there
is likely to be a threshold IL-7 concentration requirement,
below which it has no effect. The approach taken to over-
come this problem was to target IL-7 to the thymus by the
creation of a fusion protein. The molecule CCL25 is pro-
duced in the thymus [26] and binds to the chemokine
receptor CCR9 for which it is the only known ligand. A
fusion protein between the extracellular portion of CCR9
and IL-7, when used as a therapeutic agent in old animals,
results in the accumulation of the fusion protein in the
thymus, the reversal of age-associated thymic atrophy, a
significant increase in the production of new T cells and a
significant improvement in antiviral responses in old ani-
mals [26]. An example of the effect of the fusion protein
treatment is provided in Figure 2 which shows that mice
treated with the fusion protein had a lower influenza viral
load in their lungs, compared with sham-treated animals,
following influenza infection.
IL-7 clearly has an important role in thymic functioning
and these findings indicate that modulation of IL-7 may
offer a target for increasing the response to vaccination in
the elderly.
4. The challenges of immunity to infection in the 
elderly
The effects of immunosenescence on the thymus and
resulting decline in the population of naïve T cells have
already been mentioned. As the ratio of naïve T cells (i.e.,
cells that have not yet encountered a specific antigen) [27]
to memory T cells falls, the repertoire of cells available to
respond to challenges from novel pathogens shrinks
[28,29]. Theoretically, this small population of cells
should still proliferate and be functional, offering protec-
tion against new infections [27]. Furthermore, these cells
could be specifically targeted by vaccines to stimulate spe-
cific and effective immune responses. However, evidence
suggests that although these cells have a naïve phenotype
they may also have aged.
The phenotype and function of the remaining naïve T cell
population in the elderly was evaluated and compared
with those of younger people [27]. Fluorescent-activated
cell sorting (FACS) analysis was used to detect surface
markers that should be abundant in this population of
cells such as the T cell homing receptors CD62L and
CCR7. In addition, levels of CD57, the senescence marker,
were measured, which was expected to be expressed at low
levels. The results indicate that naïve T cells from the
Influenza viral load in the lungs of 20 month old mice, 6 days  after infection Figure 2
Influenza viral load in the lungs of 20 month old mice, 
6 days after infection. Copyright 2005 The American 
Association of Immunologists, Inc. *P< 0.001 when 
compared with the control group. These mice had 
expression plasmids containing either the IL-7 gene, the 
fusion protein (the extracellular portion of the chemokine 
receptor CCR9 and interleukin-7) gene, or a sham control 
gene (the N-terminal portion of CCR9) inserted into their 
anterior tibial muscle approximately 2 months previously 
[26]. Immunity & Ageing 2007, 4:9 http://www.immunityageing.com/content/4/1/9
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younger donors form a homogenous population, the
majority of which express CD62L and CCR7, with very
few cells expressing CD57 (Figure 3A) [30]. However, the
naïve T cells from elderly donors formed a much more
heterogeneous population. Approximately 40% of cells
did not express the T cell homing receptors CD62L and
CCR7, meaning these cells cannot migrate to peripheral
lymph tissue. In addition, about 10% expressed the senes-
cent marker CD57 (Figure 3A).
Further studies have shown that T cells from the elderly
with a naïve phenotype (CD45 RA+ CD28+ as well as
CD45 RA+ CD28+ CD62L+) had significantly shorter tel-
omeres, a sign of reduced proliferative potential, than
those from younger people (Figure 3B) [27,30]. In addi-
tion, the T cell receptor repertoire is restricted in all 24 Vβ
families, suggestive of the presence of clonal expansions
[27]. These changes were unexpected, since naïve T cells,
irrespective of their source, should theoretically have long
telomeres and should not have undergone clonal expan-
sion.
In theory, increasing age would be predicted to be associ-
ated with a well-functioning memory T cell population
that can respond to previously encountered pathogens.
However, this is not always the case [31]. Among several
factors that hamper the function of both naïve and mem-
ory T cells in the elderly, there is latent infection with
cytomegalovirus (CMV) [32]. CMV seropositivity has
been linked with changes of T cell phenotype and func-
tion similar to those observed in immunosenescence. In
addition, this is thought to be one of the main factors
stimulating oligoclonal expansion in CD8+ T cells. Over-
all, these findings suggest that phenotypic classification of
naïve T cells may be inaccurate in the elderly. Further-
more, CMV infection clearly contributes to the functional
decline of the immune responsiveness with age.
5. Vaccine-induced antibody responses wane 
rapidly in the elderly
Some of the wide-reaching effects of immunosenescence
have been described in the previous sections, including
the impact on the composition of the T cell pool. Evidence
suggests that in the elderly, a large proportion of the mem-
ory T cells have characteristics of replicative senescence
[33]. The potential far-reaching effects of the presence of
senescent T cells is illustrated by the correlation between
poor response to vaccination in the elderly and an
increase in the proportion of CD8+ T cells that lack expres-
sion of CD28 [34-36].
The underlying cause for the putative occurrence of repli-
cative senescence within the T cell memory pool during
aging may relate to the exquisite specificity of each lym-
phocyte. Although it is estimated that an individual CD4+
T cell can respond to approximately 3 × 105 different 11-
mer peptides [37], there is an enormous repertoire of
immune cells and the number of cells that can recognise
and respond to any single antigen may be extremely
small. Thus, to generate a sufficient quantity of specific
effector cells to fight an infection, an activated lymphocyte
must proliferate extensively before its progeny differenti-
ate into effector cells. For this reason, a limitation on the
process of cell division could potentially have devastating
consequences on immune function.
In situations of repeated interaction with an antigen over
an extended period, as occurs during chronic infections,
the relevant T cells undergo extensive proliferation, as
indicated by telomere length measurements. Studies that
model this process in cell culture using an allogeneic lym-
phoblastoid cell line as antigen have shown that extensive
antigen-driven cell division ultimately triggers an irrevers-
ible cell-cycle arrest by a process referred to as replicative
senescence. Using this same model, we have shown that
cultures of senescent CD8+ T cells also show resistance to
apoptosis, permanent loss of CD28 expression, reduced
ability to respond to stress, and an altered cytokine pro-
file. If similar changes in cytokine profiles occur in vivo, T
cell communication and response to vaccination may be
affected. An example of this alteration in cytokine profiles
is the increase in the production of tumour necrosis factor
alpha (TNF-α) and IL-6 [36], changes that occur in cell
culture, and which mirror cytokine profiles observed in
the frail elderly. Conversely, reduced production of antivi-
ral cytokine, interferon-γ, was observed in cultures of HIV-
specific senescent CD8+ T cells established from HIV+
donors (Figure 4). HIV disease shows multiple features of
premature immunological aging [37].
A further change observed in senescent CD8+ T cells is the
critically short telomere length [36]. Telomerase, an
enzyme that is upregulated in activated T cells, re-elon-
gates telomeres in vivo and the decline in the activity of
this protein is thought to play a key role in replicative
senescence. CD8+ T cells that are repeatedly stimulated
with antigen in cell culture lose the ability to activate tel-
omerase [38,39]. Gene therapy using the catalytic human
telomerase (hTERT), improves the function of these cells
[40]. These proof-of-principle studies suggest that telom-
erase-based approaches, either genetic or pharmacologic,
may retard or prevent CD8+T cell replicative senescence.
Several factors may drive T cell senescence in vivo, among
which are infections with viruses that establish latency,
such as CMV or Epstein-Barr virus (EBV). These viruses
can chronically stimulate T cells, and may be responsible
for the presence of clonal expansions of virus-specific
CD8+ T cells in the elderly [32]. Thus, in addition to tel-
omerase-based strategies for preventing or reversing thisImmunity & Ageing 2007, 4:9 http://www.immunityageing.com/content/4/1/9
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CD8+ CD45RA+CD28+ T-cells from 5 young (<35 years of age) and 5 elderly (>65 years of age) donors Figure 3
CD8+ CD45RA+CD28+ T-cells from 5 young (<35 years of age) and 5 elderly (>65 years of age) donors. A) 
Expression of CD surface markers by fluorescent-activated cell sorting (FACS) analysis [30]. Numbers in the 
graph indicate the percentage of cells in the respective quadrant. Ten identical experiments were performed. B) Flow fluo-
rescent in situ hybridisation (FISH) analysis of the relative telomere length [30]. Filled black peak represents the 
tetraploid human T-cell leukemia cell line 1301 with a known telomere length of 25 kbp (internal standard). The figure shows 
one of ten identical experiments.Immunity & Ageing 2007, 4:9 http://www.immunityageing.com/content/4/1/9
Page 7 of 9
(page number not for citation purposes)
senescence, physical removal of senescent cells has been
proposed [41]. If senescence can be prevented or reversed,
either using telomerase-based approaches or physical
intervention, this would improve the immune response
and the effectiveness of vaccination in the elderly.
6. Conclusions
The evidence presented here demonstrates the impact of
immunosenescence on multiple aspects of the immune
system. Examples of some clinical outcomes of this age-
related decline in immune function are the increased risk
of elderly persons to succumb to infections and their com-
promised response to vaccination. However, despite the
reduced response, vaccination can provide valuable pro-
tection for the elderly as prevention of diseases such as
influenza, which causes significant morbidity and mortal-
ity in this population, is more effective than treatment [4].
Furthermore, vaccination can also have an important role
in the prevention of more serious complications, for
example pneumonia, cerebrovascular accident, myocar-
dial infarction and other cardiovascular diseases follow-
ing influenza infection [42,43].
The findings discussed here illustrate the continuing chal-
lenges faced in providing effective vaccination coverage
against infectious diseases in the elderly. Among these, a
particular challenge is represented by vaccination against
influenza, due to the very heavy toll of mortality in the
elderly every year because of the reduced effectiveness of
currently available influenza vaccines in this vulnerable
age group. Better vaccine efficacy in the elderly may
require a two-pronged attack on the problem, consisting
of an improvement in the immune response and an alter-
ation to the vaccine formulation. Reversing the decline in
the immune response could be achieved by removing
senescent cells, therefore eliminating any potentially det-
rimental effects emanating from these cells, and replacing
these cells with naïve cells through increased thymic out-
put. There are several potential approaches to reversing
thymic atrophy and increasing the number of recent
thymic emigrants but very few for removing senescent
cells. The second prong of the assault on the problem
would be to produce a more effective vaccine. Several
strategies have been explored, including the use of high
dose vaccines [44,45], DNA vaccines with an immunos-
timulatory patch [46], virosomal vaccines [47] and adju-
vanted vaccines [48,49]. Adjuvanted influenza vaccines,
such as those containing the oil-in-water emulsion
MF59™ and possibly others, when available in the future,
have an important role to play in the vaccination of vul-
nerable populations. Indeed, adjuvanted influenza vac-
cines have been shown to induce stronger and more
effective serologic response in the elderly than conven-
tional non-adjuvanted vaccines, not only against homol-
ogous but also against heterovariant strains [48,49].
Adjuvanted vaccines strongly support the notion that bet-
ter vaccines can be designed with the aim of overcoming
immunosenescence and/or improving protection in the
elderly population.
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